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Abstract - Nowadays patients affected by deep vein 
thrombosis (DVT) and pulmonary embolism (PE) are 
studied widely but the challenge for physicians is 
when and how they are to be treated. Most patients 
present serious comorbidities that can potentially 
make treatment difficult. An increasing cohort of 
patients cannot be treated with systemic fibrinolysis 
but fortunately today, physicians can utilize a number 
of different instruments to resolve acute DVT and PE. 
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DVT and PE are major health problems in Europe 
with potentially serious outcomes in terms of 
mortality and morbidity, mainly because the 
relationship between the two pathologies is closely 
linked. In epidemiological studies annual incidence 
rates for PE range from 39-115 per 100,000 people 
and for DVT from 53-162 per 100,000 people.1  
Anticoagulant drugs are recognized as effective 
treatments and have been introduced into clinical 
practice for the primary prevention of DVT and PE, 
for the prevention of PE in patients with a DVT 
diagnosis and for the secondary prevention of 
recurrent venous thromboembolic events over time.2 
However, the most frequent consequence of DVT - 
post-thrombotic syndrome (PTS) - is not reduced by 
anticoagulant treatment. PTS remains the main 
problem in patients with previous DVT, with an 
incidence rate ranging from 25% to 50% in reported 
studies and a severe clinical manifestation 
characterized by ulcer development in 15% of 
patients.3 
More and more authors suggest that early treatment of 
DVT with direct thrombolysis of the catheter, 
mechanical thrombolysis and drug-mechanical 
thrombolysis, supports the idea that recanalization of 
the vein, as recently evaluated in different number of 
studies, shows promising results in terms of 
improvement in quality of life and incidence 
reduction in PTS patients. This procedure has the 
advantage of preserving the venous valve function 
after DVT thereby preventing the development of the 
main physiological factors of post-DVT venous 
hypertension such as valve reflux and late venous 
obstruction.4 They report that particular attention 
should be paid to the reflux of the valve which must 
be prevented by operating venous thrombosed 
segments in which the damage induced by 
inflammation leads to structural valve insufficiency 
and in the non-involved venous segments in which 
venous dilation distal to obstruction leads to 
functional valve failure.4  
Several studies have shown that systemic 
thrombolysis, surgical thrombectomy and direct 
catheter thrombolysis reduce PTS.5–7 
New mechanical thrombus removal devices may 
represent safe and effective treatment for acute PE, 
especially in patients with absolute contraindication 
to thrombolysis, resulting in high technical and 
clinical success with such a procedure. 8-9 Moreover, 
coexisting DVT could be treated with thrombus 
removal devices thereby avoiding caval filter 
deployment. 
Current VTE incidence is approximately 1 per 1,000 
adults annually. The majority (almost 2/3rds) of 
patients present with DVT, while the remainder 
present with PE.  1-month mortality is as high as 6% 
for DVTs and 10% for PEs, though post-mortem 
studies suggest that these mortality rates are most 
likely underestimated as autopsy results estimate 
mortality to be as high as 30% suggesting that perhaps 
many PEs are not diagnosed at the time of death.10  
 
II. THE RATIONALE FOR AN 
INTERVENTIONAL APPROACH 
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The most alarming acute complications of proximal 
lower extremity DVT are PE and phlegmasia cerulea 
dolens (PCD). PCD is a rare condition in which DVT 
causes severe pain and swelling of the entire (lower) 
extremity that results in arterial circulatory 
compromise and acute limb ischemia from markedly 
increased interstitial and venous pressure. Chronic 
complications of proximal lower extremity DVT 
(recurrent VTE and post-thrombotic syndrome (PTS) 
are frequently debilitating. VTE recurrence is 
reported to be as high as 25% and patients who do not 
undergo anticoagulation treatment for an extended 
period of time have a high risk of recurrence (over 
50%) within the successive 10 years. 11-12 PTS is 
described in up to 50% of patients within 2 years after 
diagnosis of symptomatic lower extremity DVT. 13 
The anatomic extent of DVT has been shown to 
correlate with PTS incidence and severity. DVT 
involving the iliac and common femoral veins is more 
than twice as likely to cause PTS or recurrence than 
isolated femoro-popliteal vein thrombosis.14 The 
presence of iliofemoral DVT is also a major predictor 
of severe PTS. These observations have led to the so-
called open vein hypothesis that relief of this outflow 
obstruction may prevent the development of or reduce 
severity of PTS.   
 
Catheter-based endovascular therapies 
 
The markedly high rates of bleeding complications 
from systemic thrombolysis and the invasive nature of 
surgical approaches have led to rapid adoption of 
catheter-based endovascular therapies for proximal 
and inferior vena cava DVT over the past decade. 15  
Catheter-based endovascular therapies allow 
thrombolytics to be directed at a specific, yet large, 
surface area within the thrombus (Catheter Directed 
Thrombolysis – CDT). Percutaneous Mechanical 
Thrombectomy (PMT) encompasses thrombus 
fragmentation, rheolytic thrombectomy with 
hydrodynamic catheter devices, suction 
thrombectomy with aspiration catheters and rotational 
thrombectomy. PMT can also be directly associated 
with CDT in some specific devices 
(Pharmacomechanical Cateter Directed Thrombolysis 
– PDCT) and in some cases angioplasty and stenting 
can complement and optimize the result of the 
thrombolysis. 
Results from the recently completed Acute Venous 
Thrombosis study: the Thrombus Removal with 
Adjunctive Catheter-Directed Thrombolysis 
(ATTRACT) trial, a multicenter randomized control 
trial assessing the efficacy of pharmaco-mechanical 
CDT, will help provide clinicians with high-quality 
evidence. In patients with massive PE, systemic 
thrombolytic therapy has been shown to reduce 
mortality, decrease the risk of developing Chronic 
thromboembolic pulmonary hypertension (CTEPH), 
and improve quality of life. 16-17 A recent meta-
analysis suggests that systemic thrombolytic therapy 
also reduces mortality in patients with sub-massive 
PE, but the reduction appears to be at the expense of 
significant major bleeding complications, including 
intracranial haemorrhage.18 These bleeding-related 
adverse events as well as potential treatment failure 
associated with systemic thrombolysis have resulted 
in the exploration of catheter-based thrombus removal 
as a major therapeutic option in these patients.19-20 
 
III. CURRENT GUIDELINES 
 
Based on the available literature, the latest Italian 
SICVE-SIF (2016) guidelines suggest that in selected 
cases of acute ilio-femoral DVT, when patients are 
considered at a high risk for developing complications 
(such as PCD or venous gangrene), a CDT - PCDT or 
surgical thrombectomy approach followed by oral 
anticoagulation therapy (evaluating the risk and 
benefits of the treatment), is the best course of 
treatment.  (Recommendation 12.1.9)    
For pulmonary embolism in patients with absolute 
contraindications to thrombolysis the latest European 
Society of Cardiology (ESC – 2014) guidelines 
indicate interventional options including thrombus 
fragmentation with a pigtail or balloon catheter, 
rheolytic thrombectomy with hydrodynamic catheter 
devices, suction thrombectomy with aspiration 
catheters and rotational thrombectomy. For patients 
without absolute contraindications to thrombolysis 
however, CDT or PCDT are the preferred approaches. 
21 
In line with this, American ACCP guidelines (2016) 
recommend catheter-assisted thrombus removal over 
no such intervention22 in patients with acute PE 
associated with hypotension who have a high risk of 
bleeding, failed systemic thrombolysis, or are 
susceptible to shock that is likely to cause death 
before systemic thrombolysis can take effect (e.g., 
within hours) if the appropriate expertise and 
resources are available.22  
 
IV. ENDOVASCULAR MECHANICAL 
THROMBECTOMY DEVICES 
 
Many mechanical endovascular techniques for 
thrombus removal have been explored over the last 
two decades. Starting with the simplest rotation of a 
Pig Tail and manual syringe suction there has been a 
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large development of new devices in response to the 
clinician’s need and observation. 
Some have failed to be adequately efficacious or are  
associated with unacceptable complication rates. 
Problems have included limited trackability, vessel 
injury and incomplete revascularization. One of the 
main difficulties is designing a device that can remove 
adequate volumes of variable age thrombus while also 
maintaining an acceptably small size, flexibility, and 
ease of use.  
After a review of the literature and consulting 
PubMed in the English language with a series of 
keywords related to VTE and PMT-PCDT, we 
collected information on all the currently available 
Mechanical Thrombectomy devices. These include 
rheolytic thrombectomy and aspiration devices, 
rotational thrombectomy devices, oscillatory 
pharmaco-mechanical thrombectomy and aspiration 
devices, ultrasound-enhanced pharmacomechanical 
thrombectomy devices and thromboaspiration with 
extra-corporeal circulation devices. 
The following sections describe each device, its 
characteristics and the current published literature on 
its safety and effectiveness.  
 
AngioJet ™ Thrombectomy System (Boston 
Scientific Corp) 
 
The AngioJet ™ Thrombectomy System is a rheolityc 
pharmacomechanical peripheral thrombectomy 
device with active aspiration and pulse lytic delivery. 
It is designed to remove thrombus with the Venturi-
Bernoulli effect having multiple, high-velocity and 
high-pressure saline jets which are introduced through 
orifices in the distal tip of the catheter to create a 
localized low-pressure zone resulting in a vacuum 
effect with ensuing engagement and dissociation of 
bulky thrombus.23 
The system consists of a mobile console and a wide 
variety of catheters. The AngioJet™ console monitors 
and controls the system with automated self-
configuration of each catheter and step-by-step 
procedural interface.  The Console energizes the 
pump which sends pressurized saline to the catheter 
tip. Saline jets travel backwards to create a low-
pressure zone causing a vacuum effect. The thrombus 
is sucked into the in-flow windows and the jets push 
the thrombus back down the catheter.  The thrombus 




Figure 1. AngioJet ™ Thrombectomy System. 
 
Currently available catheters from 3 F to 8 F on 
guidewires from 0,014” to 0,035” allow treatment of 
vessels from a minimum of 1,5 mm diameter.  
A total of 32 sites in the United States and Europe 
enrolled patients with DVT in the Peripheral Use of 
AngioJet™ Rheolytic Thrombectomy with a Variety 
of Catheter Lengths (PEARL) registry (Garcia MJ et 
al, 2015). 329 patients were enrolled from January 
2007 through June 2013 with 67% of the patients 
undergoing an AngioJet procedure within 14 days of 
the onset of symptoms with patient characteristics and 
outcome data collected.  
Four treatment approaches using the AngioJet ™ 
thrombectomy were applied: Rheolytic Therapy (RT) 
without lytic agent in 4% of patients, 
pharmacomechanical catheter-directed thrombolysis 
(PCDT) in 35%, PCDT and catheter-directed 
thrombolysis (CDT) in 52%, and RT in combination 
with CDT in 9%. The 3-, 6-, and 12-month freedom 
from rethrombosis rates were 94%, 87%, and 83%, 
respectively. Major bleeding events occurred in 12 
patients (3.6%), none of which were related to the 
AngioJet ™ procedure. 
Authors concluded that the PEARL registry data 
demonstrates that rheolytic PCDT treatment of DVT 
is safe and effective and can potentially reduce the 
need for concomitant CDT and intensive care.24 
 
Indigo ™ Percutaneous Thrombectomy System 
(Penumbra)  
 
Penumbra’s Indigo System was created for cerebral 
vessel thromboaspiration in stroke and cerebral sinus 
thrombosis. With the recent addition of larger 6- and 
8-F systems and a venous indication, the Penumbra 
Indigo® System requires a more powerful, larger-
bore aspiration catheter with greater trackability to the 
peripheral vasculature to evacuate greater thrombus 
burdens from large vessels. 
Indigo system’s technology helps to maintain 
continuous aspiration, limiting clogging of the 
catheter’s tip. This percutaneous system is available 
in four diameter options (4-8 Fr) with lengths ranging 
from 85 to 150 cm, allowing smaller-diameter 
catheters to work coaxially through larger-diameter 
catheters to treat long lesions in tapering vessels. 
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It is able to provide rapid restoration of flow to 
thrombosed vessels in settings in which there is 
inadequate time to allow thrombolysis to work. It can 
also be used for revascularization when thrombolytic 
therapy and surgery are contraindicated or prior to 
thrombolysis in order to decrease thrombus burden 
and potentially shorten lengthy infusion times. 
Finally, the Indigo System can be effective in 
removing more organized, subacute-to-chronic 
thrombus after thrombolytic therapy has failed.25 
Extensive literature is available on Indigo 
thrombectomy for cerebral venous sinus thrombosis 
and for acute stroke but only a few case reports exist 
on Indigo Trombectomy for DVT. One of these, 
Vadlamudi V. (2016), reports thrombectomy with the 
Indigo System for a case of PCD, with a rapid 
restoration of the vessel patency and a solution to the 
symptoms, avoiding risk of amputation. He concludes 
that in cases of DVT when rapid debulking of 
thrombus burden is necessary and thrombolysis may 
not be feasible, thrombectomy with the Indigo System 
provides an efficient solution utilizing a trackable 





The AngioVac system is manufactured by Vortex 
Medical for AngioDynamics and is approved by The 
U.S. Food and Drug Administration (FDA) “to 
remove fresh, soft thrombi or emboli during 
extracorporeal bypass for up to 6 hours.” It consists of 
a 22F suction cannula and is combined with a veno-
venous bypass circuit and a reinfusion cannula.  
While on a bypass circuit, the blood passes through a 
filter canister which traps any undesired material such 
as thrombus before being reinfused into the patient via 
a reinfusion cannula. The tip of the suction cannula is 
designed with an expandable balloon funnel to 
optimize the aspiration and engagement area. The 
current design is available either with a straight or a 
20 degree angle tip.  
The advantage of the AngioVac over other existing 
devices is the large bore aspiration cannula which 
allows for aspiration of large volumes of thrombus.  
It differs from the rheolytic devices such as AngioJet 
(Boston Scientific) which can cause significant 
hemolysis and arrhythmias.  AngioVac procedures are 
performed under general anesthesia. Both sides of the 
neck and both groins should be prepped for possible 
access. The patient is then fully anticoagulated with 
heparin (ACT > 300 sec). The right internal jugular 
vein is the preferred access for cases of IVC 
thrombosis and pulmonary artery thrombosis, but 
common femoral vein access is preferred in patients 
with superior vena cava thrombus and thrombus on 
central venous catheters. The infusion cannula is 
placed in an internal jugular vein or common femoral 
vein which is not used for the AngioVac and where 
there is no thrombus. A 26F DrySeal sheath is inserted 
over a stiff guide wire under fluoroscopic guidance. 
Through this sheath, the 22F AngioVac cannula is 
placed over the wire.  The AngioVac catheter is then 
slowly advanced against the thrombus and moved to 
and fro until the thrombus is aspirated. Special 
attention is needed when the cannula is advanced 
across IVC filters as the cannula can engage the filters 
and cause mangling or even displacement of the 
filter.27 
Donaldson CW et al (2015) reports the first significant 
case series describing AngioVac use, feasibility and 
outcome in evacuating large caval thrombi or 
intracardiac masses in PE. 14 consecutive patients 
were retrospectivey analysed and treated with 
AngioVac Thrombectomies between April 2010 and 
July 2013 at their institution. Four patients (27%) 
were in shock at the start of the procedure. Peri-
procedure mortality was 0% and in-hospital mortality 
was 13% at a mean follow-up of 23 days. No 
pulmonary hemorrhages, strokes or myocardial 
infarctions took place. Though 73% of the patients 
had a post procedural drop in hematocrit, only two 
bleeding events were related to the access site and 
required a transfusion. The authors concluded that 
AngioVac thrombectomy is feasible in critical 
patients with acute DVT or PE and large caval 
thrombi or intracardiac masses.28 
 
Aspirex (Straub Medical) 
 
The Aspirex® System combines mechanical 
rotational clot fragmentation and active negative-
pressure removal of thrombus particles to prevent 
distal embolization. It consists of a suction console 
operated by hand or footswitch and the catheter is 
available in different sizes (6-8-10 Fr). Several 
successful in vitro studies have been followed by the 
pursuit of different applications and the device has 
been used successfully in the treatment of acute-to- 
chronic thrombo-embolic arterial occlusions of the 
limbs, DVT, hemodialysis access grafts, bypasses, 
stents, pulmonary artery occlusion and inferior vena 
cava and aortohepatic bypass occlusions.  
Eidt-Lidt G et al (2008) reported their experience with 
the Aspirex device on acute PE. From July 2004 to 
May 2007 18 patients who had met the criteria for 
massive PE underwent thrombus fragmentation using 
a pigtail catheter that was complemented in 13 
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patients with thrombus aspiration. The Aspirex 
percutaneous thrombectomy device was used in 11 of 
the patients. Hemodynamic, angiographic, and blood 
oxygenation parameters improved after the 
procedure. A significant increase was observed for 
systolic systemic BP as was a decrease in mean 
pulmonary artery pressure. The in-hospital major 
complication rate was 11.1%; one patient died from 
refractory shock, and one patient had an intracerebral 
hemorrhage (minor neurologic sequelae). No 
cardiovascular deaths or recurrent pulmonary 
thromboembolism were documented during the 
clinical 1-year follow-up. The group concluded that in 
patients with massive PE, right ventricular 
dysfunction and major contraindications to 
thrombolytic therapy, failed thrombolysis, or 
unavailable surgical thrombectomy, mechanical 
percutaneous thrombectomy appears to be a useful 
therapeutic alternative.29 
 
Trellis ™ Thrombectomy System (Covidien- 
Medtronic) 
 
 The redesigned Trellis ™system is a 
pharmacomechanical thrombolysis device that 
enables focused treatment of blood clots in cases of 
DVT. This latest Trellis system has been optimized to 
enhance drug delivery and removal of the dissolved 
clot. The system consists of an over-the-wire catheter 
with two occlusive balloons to close off the treatment 
area and target the drug release, an infusion zone to 
deliver the lytic drug and an oscillation drive unit that 
disperses the drug and mechanically dissolves the 
clot. Additionally, the new system features a larger 
aspiration window than the previous version which 
allows a better removal of the drug and the dissolved 
clot. 
The multicenter isolated-pharmacomechanical 
thrombolysis device (ISOL-8, Gagne P et al, 2015) 
study was designed to determine the safety and 
efficacy of the Trellis™-8 peripheral infusion system 
when used as primary intervention in cases of DVT, 
proximal lower-extremity occlusive DVT, and to 
track the incidence and severity of the post-
thrombotic syndrome (PTS) 2 years after treatment. 
Data from patients treated with the Trellis™-8 system 
were retrospectively collected from six centers, 
including patients with occlusive lower-extremity 
DVT involving at least the iliac and/or common 
femoral vein. Patient data, procedure outcomes, 
complications and follow-up venous duplex and 
Venous Clinical Severity Scores (VCSS) were 
collected throughout a 24-month period.  
A total of 151 limbs in 139 patients were treated. After 
treatment, 43.7% of the limbs showed evidence of 
chronic thrombus. The average amount of 
thrombolysis, as determined by a venogram, was 
highest in patients who had acute thrombus (81 ± 
19.7%) compared with those who had subacute 
thrombus (61 ± 22.5%) and complex cases involving 
acute and/or subacute thrombus on chronic scars (56 
± 26.5%).  
VCSS scoring showed that the number of patients 
with none and/or mild pain, varicose veins, and skin 
changes at 1-month remained stable at 12 months 
whereas the percentage of patients with none and/or 
mild venous edema improved from 71.7% at 1 month 
(38 of 53) to 86.8% (46 of 53) at 12 months. No 
clinically significant pulmonary emboli or major 
periprocedural bleeding events were reported. 
Authors concluded that patients with acute lower-
extremity DVT involving the proximal veins could be 
safely and successfully treated with the Trellis™ 
System with no reports of procedural bleeding and 
low occurrence of severe PTS after primary treatment. 
30 
 
Cleaner XT (Argon Medical Devices) 
 
The Cleaner Thrombectomy System was at first 
indicated for the mechanical declotting of native 
vessel dialysis fistulae and synthetic dialysis access 
grafts but in 2014 Argon Medical Devices received 
clearance from the US Food and Drug Administration 
to begin marketing the CLEANER XT™ and 
CLEANER 15™ Rotational Thrombectomy Systems 
for mechanical declotting and controlled and selective 
infusion of physician-specified fluids, including 
thrombolytics, in the peripheral vasculature.  
The Cleaner Thrombectomy System consists of a 
single sinusoidal wire design that safely macerates 
thrombus while preserving the vessel: a fluid vortex 
effectively macerates thrombus while reducing the 
risk of endothelial damage wall. The guidewire-like 
design provides good steerability and the 3-way 
sideport distal side hole on the catheter allows for 
infusion of thrombolytics and contrast media. 
Koksoy C. et al (2014) reported the results of a 
retrospective study evaluating the use of the Cleaner 
Thrombectomy Device in acute or subacute VT. They 
analysed 41 patients with acute or subacute DVT 
treated with the Cleaner Thrombectomy Device 
between July 2012 and August 2013. The device was 
used in a single-session technique for patients with 
lower-extremity DVT.  
Based on contrast venography, the extent of lysis was 
graded from I (< 50%) to III (complete). Sixteen 
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patients (39.0%) had femoropopliteal thrombosis and 
25 (61.0%) iliofemoral venous thrombosis. The mean 
duration of symptoms was 11.0 days. The mean 
quantity of the tissue plasminogen activator was 20.7 
mg, and the mean duration of the procedure was 74.3 
min. At the end of the PMT procedure, 70.7% of 
patients had complete (grade III) thrombus resolution. 
Grade I lysis were noted in one 2.4% of the patients 
and grade II lysis in 26.8%. Thirty-eight of the 41 
patients were treated with PMT in a single session and 
three (7.3%) required an additional lytic infusion as a 
result of residual thrombi. The overall grade III, II, 
and I thrombus resolution rates, including the 
supplemental thrombolysis, were 73.2% (n = 30), 
22.0% (n = 9) and 4.9% (n = 2), respectively. No 
mortalities occurred.  
The authors concluded that the use of the Cleaner 
Thrombectomy Device is a promising alternative to 
current treatment modalities for the management of 
DVT in a single session.31 
 
Arrow Trerotola™ PTD® Percutaneous 
Thrombolytic Device (Teleflex) 
 
The Arrow-Trerotola PTD was created for 
hemodialysis accesses mechanical thrombectomy but 
it has been also widely used for DVT thrombectomy.  
A mechanical thrombectomy catheter with a flexible 
tip and activated spinning basket, a hand-held 
disposable rotator drive unit and an introducer sheath 
(5-7 Fr) make up the system. The activated spinning 
basket macerates the thrombus, a catheter lumen 
sidearm permits catheter flushing during preparation 
and use, and introducer sheath and large-bore sidearm 
assembly simplifies thrombus removal. 
Park KM et al (2014) studied patients who had 
undergone treatment for acute iliofemoral DVT from 
January 2005 to December 2011 at 2 institutions. The 
treatment outcomes with the Trerotola in the 
mechanical-thrombectomy (MT) group were 
compared with those obtained with Catheter-direct 
Thrombolysis (CDT) alone and with MT plus CDT. 
A total of 98 DVTs were treated. 53 with the MT and 
45 with the CDT. No statistical differences were 
found in the clinical characteristics among the MT 
with CDT, MT only and CDT group. Symptom 
improvement was seen in 78% of the MT group, 80% 
of the MT with CDT group, and 71% (32 limbs) in the 
CDT group (P = 0.498). No difference was noted in 
complications during the procedures or in primary 
patency rates during the follow-up period. 
Authors concluded that MT with the Trerotola device 
for acute iliofemoral DVT requires shorter procedure 
times and lower urokinase doses than conventional 
CDT while providing the same results.32 
 
Ekosonic ™ endovascular system (EKOS™ 
Corporation, BTG International group company) 
 
The EkoSonic™ Endovascular system with Acoustic 
Pulse Thrombolysis™ treatment uses targeted 
ultrasonic waves in combination with clot-dissolving 
drugs. The system uses a specific catheter and an 
ultrasonic core to effectively target an entire clot. The 
acoustic pulse field makes the fibrin more porous 
while creating a pressure gradient which transports 
the clot-dissolving drug deep inside the clot 
increasing clot dissolution without mechanically 
damaging vessels, valves or walls. At the same time 
the acoustic enhancement requires up to four times 
less drug dosage than traditional systemic delivery.33-
34 (figure 2) 
 
 
Figure 2. Ekosonic ™ endovascular system. 
 
Zaghlool DS et al. (2016) followed a large sample 
population over a 5-year period to evaluate their 
experience with the EkoSonic endovascular system. 
Their aim was to prove that ultrasound-accelerated 
thrombolysis (UAT) provides excellent thrombolysis 
and midterm patency rates with minimal thrombolytic 
complications. Primary end points were the 
achievement of the complete thrombolysis. The 
secondary end point was to analyze the thrombolytic 
usage, complication rates, and midterm patency over 
a 1-year period35. A total of 48 limbs were treated with 
EkoSonic. Forty cases were diagnosed as acute 
whereas the remaining 8 were chronic. Complete 
thrombolysis was successful in 38 out of 48 (79%) of 
patients and partial thrombolysis was achieved in 10 
out of 48 (21%) of patients. A total of three 
complications (6%) took place, all of which were 
minor bleeding. One-year patency was 87% with no 
signs of valvular reflux, comparable to published data 
using conventional catheter-directed thrombolysis.35 
The clinical use of catheter directed thrombolysis with 
the EkoSonic Endovascular System (EKOS) in 
patients with acute PE had never before been 
evaluated. Catheter directed thrombolysis is an 
effective treatment modality for high risk PE patients 
with failed systemic thrombolysis (ST). J Sag S et al. 
(2016) collected thirteen consecutive patients with 
failed ST who had been treated with EKOS catheters 
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and tissue plasminogen activator (t-PA) in 
combination with unfractionated heparin. The 
duration of EKOS treatment was 21.8 ± 3.8 h and the 
total dose of tPA was 31.2 ± 15.3 mg. One patient who 
presented with cardiac arrest died. The clinical status 
of the remaining subjects improved significantly with 
improvement of right ventricular functions and 
decrease of systolic pulmonary artery pressure 
without any hemorrhagic complication. None of the 
patients had died or suffered recurrent PE during a 
follow-up period of 6 months. Authors concluded that 
EKOS is an effective treatment modality for high risk 
PE patients with failed ST and can be applied with 
very low haemorrhagic complications.36 
 
V. CONCLUSIONS 
In our preliminary analysis, simultaneous treatment 
of DVT and PE with the thromboaspiration devices 
presented herein appears to be safe and effective. Low 
complication rates encourage the extensive use of this 
technique in selected patients, however larger 
prospective studies are needed to assess this single 
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